Patents Assigned to AIMM Therapeutics B.V.
  • Therapeutic anti-CD9 antibody
    Patent number: 11136407
    Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 5, 2021
    Assignee: AIMM Therapeutics B.V.
    Inventors: Hergen Spits, Paula Maria Wilhelmina Van Helden, Remko Schotte, Wouter Pos, Christien Fatmawati, Danïel Michiel Go, Koen Wagner, Julien Christian Villaudy
  • Means and methods for influencing the stability of cells
    Patent number: 10774308
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 15, 2020
    Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, AIMM THERAPEUTICS B.V.
    Inventor: Hergen Spits
  • Means and methods for determining T cell recognition
    Patent number: 10690658
    Abstract: The invention provides improved screening methods for testing T cell recognition of T cell epitopes.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: June 23, 2020
    Assignees: AIMM THERAPEUTICS B.V., STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Carsten Linnemann, Laura Bies, Marit Martha van Buuren, Antonius Nicolaas Maria Schumacher, Hergen Spits, Remko Schotte
  • Means and methods for producing stable antibodies
    Patent number: 10611829
    Abstract: The invention provides means and methods for selecting and producing stable antibodies against an antigen of interest, using stable ex vivo B cell cultures.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: April 7, 2020
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Mark Jeroen Kwakkenbos, Koen Wagner, Adrianus Quirinus Bakker
  • Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
    Patent number: 10556963
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 11, 2020
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Marijn Aletta Gillissen, Adrianus Quirinus Bakker, Mette Deborah Hazenberg, Martijn Kedde
  • Means and methods for producing high affinity antibodies
    Patent number: 10344076
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 9, 2019
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker
  • Therapeutic Anti-CD9 Antibody
    Publication number: 20190023803
    Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Applicant: AIMM Therapeutics B.V.
    Inventors: Hergen SPITS, Paula Maria Wilhelmina VAN HELDEN, Remko SCHOTTE, Wouter POS, Christien FATMAWATI, Danïel Michiel GO, Koen WAGNER, Julien Christian VILLAUDY
  • Means and methods for influencing the stability of cells
    Patent number: 10077427
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: September 18, 2018
    Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, AIMM THERAPEUTICS B.V.
    Inventor: Hergen Spits
  • RSV G protein specific antibodies
    Patent number: 10017562
    Abstract: The invention relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The invention further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 10, 2018
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Etsuko Yasuda
  • Means and methods for producing high affinity antibodies
    Patent number: 9969795
    Abstract: The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: May 15, 2018
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker, Koen Wagner
  • Gram-positive bacteria specific binding compounds
    Patent number: 9927428
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: March 27, 2018
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Means and methods for influencing the stability of antibody producing cells
    Patent number: 9822339
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: November 21, 2017
    Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Ferenc A. Scheeren, Tim Beaumont, Sean A. Diehl
  • Influenza A virus specific antibodies
    Patent number: 9718874
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: August 1, 2017
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker
  • RSV G protein specific antibodies
    Patent number: 9718876
    Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: August 1, 2017
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Etsuko Yasuda
  • Gram-positive bacteria specific binding compounds
    Patent number: 9688745
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: June 27, 2017
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Gram-positive bacteria specific binding compounds
    Patent number: 9458228
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: October 4, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Gram-positive bacteria specific binding compounds
    Patent number: 9399673
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 26, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Means and methods for producing high affinity antibodies
    Patent number: 9273118
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: March 1, 2016
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Hergen Spits, Mark J. Kwakkenbos, Adrianus Q. Bakker
  • Gram-positive bacteria specific binding compounds
    Patent number: 9266943
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: February 23, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Means and methods for producing high affinity antibodies
    Patent number: 9206247
    Abstract: Described are means and methods for producing high-affinity antibodies against an antigen of interest, using stable B-cell cultures.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: December 8, 2015
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker, Koen Wagner